Safety and efficacy of vigabatrin and carbamazepine. CPMP. The Committee for Proprietary Medicinal Products. (Record no. 10490800)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01172 a2200325 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250513194055.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 199911s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 0140-6736 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1016/s0140-6736(05)76241-3 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Elferink, A J |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 19991119 |
| 245 00 - TITLE STATEMENT | |
| Title | Safety and efficacy of vigabatrin and carbamazepine. CPMP. The Committee for Proprietary Medicinal Products. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Lancet (London, England) |
| Date of publication, distribution, etc. | Oct 1999 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1387-8 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Comment; Comparative Study; Letter |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Anticonvulsants |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Carbamazepine |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Child |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Epilepsies, Partial |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Risk Assessment |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Vigabatrin |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Visual Fields |
| General subdivision | drug effects |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Toivonen, M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | van Bronswijk, H |
| 773 0# - HOST ITEM ENTRY | |
| Title | Lancet (London, England) |
| Related parts | vol. 354 |
| -- | no. 9187 |
| -- | p. 1387-8 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1016/s0140-6736(05)76241-3">https://doi.org/10.1016/s0140-6736(05)76241-3</a> |
| Public note | Available from publisher's website |
No items available.